

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Berka et al.

Serial No.: 09/482,788

Group Art Unit: 1652

Filed: January 13, 2000

Examiner: Tung, P.

For: Methods For Producing Polypeptides In Cyclohexadepsipeptide-Deficient Cells

FEB (14 2002

01/31/2002 NMOHAMM1 00000094 501701

09482788

01 FC:103

144.00 CH

AMENDMENT

TECH CENTER 1600/2900

Commissioner for Patents Washington, DC 20231

Sir:

In response to the Office Action dated June 26, 2001, please amend the above-captioned application as follows:

IN THE CLAIMS

Please cancel claims 1-3, 8, 9, 13, 22-24, 30, 31, 37, 42, 50, 53, 57-59, 63, and 64 without prejudice or disclaimer. Please add new claims 70-97 as follows:

- 70. A method for producing a secreted heterologous polypeptide, comprising:
- (a) cultivating a mutant cell of a parent filamentous fungal cell under conditions conducive for the production of the secreted heterologous polypeptide, wherein (i) the mutant cell comprises a first nucleic acid sequence encoding the secreted heterologous polypeptide, and (ii) the mutant cell produces less of a cyclohexadepsipeptide than the parent filamentous fungal cell when cultured under the same conditions; and
 - (b) isolating the secreted heterologous polypeptide from the cultivation medium.
- 71. The method of claim 70, wherein the filamentous fungal cell is an Acremonium, Aspergillus, Aureobasidium, Cryptococcus, Filibasidium, Fusarium, Gibberella, Humicola, Magnaporthe, Mucor,

Attorney Docket No.: 5778.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Berka et al.

Serial No.: 09/482,788

Group Art Unit: To be assigned

Filed: January 13, 2000

Examiner: To be assigned

Confirmation No: 7465

For: Methods for producing polypeptides in cyclohexadepsipeptide-deficient cells

FEB 0 4.2002 TECH CENTER 1600/2900

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents Washington, DC 20231

Sir:

JAN 2 8 2002

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed June 26, 2001.

It is respectfully requested that the time for response to the Office Action be extended for a period of 3 months from September 27, 2001 to December 26, 2001. The required fee for the extension is estimated to be \$890.00.

The fee for claims has been calculated as shown below:

Total: 28 - 20 = 8 x 18 =

\$144.00

Independent: $2 - 3 = 0 \times 84 =$

\$0.00

Total additional fee for claims required is \$144.00.

Please charge the required extension and claims fees, estimated to be \$1034.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: December 20, 2001

Robert L. Starnes, Reg. No. 41,324

Novozymes Biotech, Inc. 1445 Drew Avenue

Davis, CA 95616 (530) 757-8100

PATENT PATENT

Attorpey Docket No.: 5778.200-US

JAN 2 8 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Berka et al.

Serial No.: 09/482,788

Group Art Unit: 1652

Filed: January 13, 2000

Examiner: P. Tung

Confirmation No: 7465

For: Methods for producing polypeptides in cyclohexadepsipeptide-deficient cells

RECEIVED

FEB 0 4 2002

TECH CENTER 1600/00

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Amendment Fee Transmittal (in duplicate)
- 2. Amendment and Marked Up Version pursuant to 37 C.F.R. 1.21

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on December 20, 2001.

Seleste A. Buriani

(name of person mailing paper)

(signature of person mailing paper)